Stocktoria
Sino Biopharmaceutical Limited 1177.HK
Sino Biopharmaceutical Limited statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (CN¥2.24); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Sino Biopharmaceutical Limited trades at about 36.8× earnings — near its 10-year norm (10-year range 14.7×–51.2×, median 37.4×).
Shaded band = 10-year range (14.7×–51.2×); dot = today's 36.8×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 82.1% | 81.5% | 81.0% | 82.8% |
| Operating margin | 21.7% | 21.9% | 23.2% | 21.1% |
| Net margin | 7.4% | 12.1% | 8.9% | 9.8% |
| FCF margin | 23.8% | 18.1% | 16.6% | 17.5% |
| Return on assets | 3.1% | 5.4% | 3.7% | 4.0% |
| Return on equity | 7.6% | 11.0% | 7.7% | 8.6% |
| Debt / equity | 0.25× | 0.06× | 0.04× | 0.13× |
| Current ratio | 1.37 | 1.26 | 1.05 | 1.29 |
Computed from company filings · HK · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.